LYEL CIK: 1806952

Lyell Immunopharma, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
−126
FY22:
−170
FY23:
−164
FY24:
−162
FY25:
−150
Change from FY21 to FY25
millions USD
FY21:
−122
FY22:
−11.5
FY23:
184
FY24:
122
FY25:
54.1
Change from FY21 to FY25
millions USD
FY21:
401
FY22:
10.6
FY23:
1.74
FY24:
1.33
FY25:
50.4
millions USD
FY21:
153
FY22:
−170
FY23:
22.1
FY24:
−38.6
FY25:
−45.5
(positive)
Change from FY21 to FY25
millions USD
FY21:
−192
FY22:
−194
FY23:
−166
FY24:
−163
FY25:
−151

All amounts in millions USD Data source:SEC EDGAR